Christopher M Rombaoa, MD
Gastroenterology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: California Pacific Medical Center - Mission Bernal · California Pacific Medical Center- Van Ness Campus · California Pacific Medical Ctr-Davies Campus Hosp. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Rombaoa’s office at (415) 600-0140 to ask if they take your plan before you enroll.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- California Pacific Medical Center - Mission BernalSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.322, Oct 2024 – Sep 2025
- California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
- California Pacific Medical Ctr-Davies Campus HospSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · No emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.187, Oct 2024 – Sep 2025
See every measure and the patient survey for California Pacific Medical Center - Mission Bernal
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 3 the same, 3 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.322 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.19 to 2.28) · 336 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.47 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 163.19 (101.27 to 225.11) · 28 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 44 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.6 · 155 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.4 · 177 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.6 · 32 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 1,281 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.42) · 2,912 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.04 to 0.45) · 2,681 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.07 (1.81 to 6.33) · 787 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.61 (0 to 3.31) · 425 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.46 (0.79 to 4.12) · 755 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.36 (0 to 16.38) · 431 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.47 (1.38 to 9.55) · 401 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.7 (0.2 to 3.2) · 105 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 1.16) · 2,291 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 2.4 · 369 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.602 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.618 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 242 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 20.9 · 197 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 39.6 · 203 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 292 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 353 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.9 · 74 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 110 cases | No different | Jan 2024 – Dec 2024 |
What patients said (406 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 74% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.224 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.325 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.373 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.3 to 1.97) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.81 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.86 (151.51 to 234.22) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 356 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.49) · 6,430 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.3 (1.5 to 5.09) · 2,196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.21 to 3.74) · 925 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.37 to 3.88) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.13 (6.06 to 14.2) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.26 (4.67 to 9.85) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.31 to 3.03) · 832 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.85) · 5,406 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.443 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.7 · 418 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 260 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.6 to 7.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (7.7 to 13.5) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 11 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.7) · 551 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 219 cases | No different | Jan 2024 – Dec 2024 |
What patients said (478 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for California Pacific Medical Ctr-Davies Campus Hosp
Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 4 the same, 1 worse of 5 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.187 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.02 (0 to 2.09) · 232 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.56 to 1.4) | No different | Jul 2022 – Jun 2024 |
| Death rate for heart failure patientsComplications and deaths | 10 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.1 · 106 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 257 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 721 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.03 to 0.49) · 2,031 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.45) · 2,032 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.35 (0.94 to 5.76) · 419 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.41 (0 to 3) · 211 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.84 (1.24 to 4.44) · 414 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.95 (2.91 to 20.98) · 218 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.61 (1.47 to 9.75) · 198 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.22 to 3.26) · 52 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.32 (0 to 1.28) · 1,461 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.6 · 58 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.756 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 91 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 65.3 · 84 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -26.6 · 115 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 142 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 55 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 25 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 312 cases | No different | Jan 2024 – Dec 2024 |
What patients said (602 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
Original Medicare doctor bills
$69,393
Medicare paid this office $69,393 for 218 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 70 | $19,644 | $164 |
| Return visit (30+ min) | 58 | $9,239 | $117 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 23 | $5,289 | $230 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $5,054 | $105 |
| New patient visit (45+ min) | 26 | $3,693 | $142 |
See all 12 services
| Long return visit (40+ min) | 70 | $19,644 | $164 |
| Return visit (30+ min) | 58 | $9,239 | $117 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 23 | $5,289 | $230 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $5,054 | $105 |
| New patient visit (45+ min) | 26 | $3,693 | $142 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 30 | $2,662 | $89 |
| Biopsy of large bowel using a flexible endoscope | 22 | $2,375 | $108 |
| New patient visit (60+ min) | 12 | $2,286 | $190 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,197 | $116 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,002 | $154 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 84 | $1,607 | $15 |
| Study of esophageal sensation by balloon distension | 13 | $481 | $37 |
Procedures Medicare counted
| Colonoscopy | 44 | More than 61% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 47 | More than 62% of doctors who do this |
Who their Medicare patients are
218 Original Medicare patients in 2024. Average age 72 · Under 65 12% · 85 and older 13% · Women 55% · Also on Medicaid 28% · Health risk score 1.39. At or below the middle of the specialty; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 65% · Depression 27% · Chronic kidney disease 25% · Coronary heart disease 24% · Diabetes 23% · Atrial fibrillation 18% · Cancer 17% · Heart failure 16% · COPD 13% · Stroke 9% · Dementia 6%.
The office billed $447,415, Medicare allowed $88,815 and paid $69,393; for 597 services of 33 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 218 | 597 | 72 | 1.39 | $447,415 | $69,393 |
| 2023 | 231 | 470 | 71 | 1.58 | $421,306 | $65,864 |
| 2022 | 190 | 467 | 72 | 1.50 | $370,943 | $60,611 |
| 2021 | 90 | 194 | 70 | 1.93 | $153,547 | $24,568 |
| 2018 | 68 | 200 | 71 | 3.24 | $92,038 | $15,683 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Long return visit (40+ min) | 76 | $18,917 | $156 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $6,045 | $106 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 24 | $5,706 | $238 |
| New patient visit (45+ min) | 26 | $3,795 | $146 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,776 | $157 |
| New patient visit (60+ min) | 19 | $3,727 | $196 |
| Biopsy of large bowel using a flexible endoscope | 28 | $3,252 | $116 |
| Return visit (30+ min) | 25 | $3,135 | $116 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 28 | $2,838 | $101 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 11 | $2,285 | $208 |
| Study of esophagus to assess movement | 11 | $593 | $54 |
2022: 11 services
| Long return visit (40+ min) | 59 | $15,359 | $148 |
| New patient visit (60+ min) | 41 | $7,565 | $185 |
| Return visit (30+ min) | 35 | $5,248 | $117 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 20 | $4,123 | $206 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 33 | $3,281 | $99 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $3,080 | $171 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $2,615 | $90 |
| New patient visit (45+ min) | 18 | $2,561 | $142 |
| Study of esophagus to assess movement | 20 | $1,173 | $59 |
| Study of rectum sensitivity and function | 12 | $931 | $78 |
| Monitoring and recording of esophageal function through nasal tube with electrode | 17 | $756 | $44 |
2021: 6 services
| Long return visit (40+ min) | 19 | $3,909 | $170 |
| New patient visit (60+ min) | 15 | $2,976 | $198 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $2,401 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,148 | $179 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 17 | $1,764 | $104 |
| Study of esophagus to assess movement | 11 | $659 | $60 |
2018: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 41 | $6,581 | $65 |
| Hospital discharge day management, more than 30 minutes | 28 | $2,765 | $99 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,547 | $182 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,514 | $108 |
Medicaid work
$516 in 2023
Medicaid paid $516 for 12 billed services this clinician did in 2023, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 12 | $516 |
| 2023 | 12 | 1 | 12 | $516 |
Drugs they prescribed that Part D paid
$237,018
Pharmacies billed $237,018 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 599) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.
406 generic and 193 brand-name prescriptions · $237,018 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Linzess | 47 | $44,552 | $948 |
| Creon | 17 | $41,689 | $2,452 |
| Motegrity | 16 | $9,505 | $594 |
| Trulance | 12 | $9,388 | $782 |
| Sucralfate | 36 | $8,338 | $232 |
See all 13 drugs
| Linzess | 47 | $44,552 | $948 |
| Creon | 17 | $41,689 | $2,452 |
| Motegrity | 16 | $9,505 | $594 |
| Trulance | 12 | $9,388 | $782 |
| Sucralfate | 36 | $8,338 | $232 |
| Rabeprazole | 76 | $5,972 | $79 |
| Sod Sulf-Potass Sulf-Mag Sulf | 86 | $5,466 | $64 |
| Omeprazole | 70 | $939 | $13 |
| Dicyclomine | 21 | $526 | $25 |
| Famotidine | 39 | $437 | $11 |
| Amitriptyline | 14 | $271 | $19 |
| Pantoprazole | 15 | $258 | $17 |
| Escitalopram | 13 | $69 | $5 |
Year by year
| 2024 | 599 | 183 | 0% (0) | 32% | $237,018 |
| 2023 | 534 | 181 | 0% (0) | 31% | $174,686 |
| 2022 | 412 | 128 | 0% (0) | 35% | $433,689 |
| 2021 | 131 | 52 | 0% (0) | 44% | $37,055 |
| 2020 | 107 | 43 | 0% (0) | 43% | $106,101 |
| 2019 | 41 | 22 | None | 32% | $30,599 |
| 2018 | 91 | 22 | None | None | $5,772 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Linzess | 22 | $22,908 | $1,041 |
| Rabeprazole | 71 | $7,852 | $111 |
| Trulance | 11 | $6,484 | $589 |
| Sod Sulf-Potass Sulf-Mag Sulf | 79 | $6,042 | $76 |
| Sucralfate | 20 | $5,400 | $270 |
| Lubiprostone | 21 | $3,602 | $172 |
| Omeprazole | 52 | $1,172 | $23 |
| Famotidine | 33 | $696 | $21 |
| Dicyclomine | 20 | $345 | $17 |
| Pantoprazole | 13 | $259 | $20 |
| Gavilyte-C | 13 | $202 | $16 |
| Hydralazine | 11 | $180 | $16 |
| Metoprolol | 14 | $83 | $6 |
2022: 12 drugs
| Linzess | 22 | $19,808 | $900 |
| Sucralfate | 28 | $6,701 | $239 |
| Lubiprostone | 21 | $6,645 | $316 |
| Suprep | 33 | $3,808 | $115 |
| Sod Sulf-Potass Sulf-Mag Sulf | 15 | $1,306 | $87 |
| Omeprazole | 41 | $974 | $24 |
| Dicyclomine | 34 | $538 | $16 |
| Pantoprazole | 18 | $515 | $29 |
| Famotidine | 20 | $471 | $24 |
| Metoclopramide | 11 | $167 | $15 |
| Amitriptyline | 14 | $91 | $7 |
| Lactulose | 13 | $81 | $6 |
2021: 3 drugs
| Linzess | 17 | $8,684 | $511 |
| Suprep | 14 | $1,547 | $111 |
| Omeprazole | 25 | $312 | $12 |
2020: 3 drugs
| Vemlidy | 27 | $32,425 | $1,201 |
| Ursodiol | 13 | $3,302 | $254 |
| Omeprazole | 12 | $231 | $19 |
Money from drug and device companies
$4,288 in 2025
| 2025 | 15 | 44 | $3,206 | $4,288 |
| 2024 | 10 | 38 | None | $1,253 |
| 2023 | 5 | 10 | None | $226 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Olympus Medical Systems | Evis Exera II Small Intestinal Videoscope | $3,206 | 1 payment
|
| Abbvie | Rinvoq | $274 | 11 payments
|
| Lilly USA | Omvoh | $196 | 6 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $138 | 6 payments
|
| Janssen Biotech | Tremfya | $94 | 3 payments
|
| Ardelyx | Ibsrela | $74 | 3 payments
|
See all 44 published payments
| Celltrion USA | Meals · 2025-12-18 | Vegzelma | $18 |
| Aimmune Therapeutics | Meals · 2025-12-17 | Zenpep | $27 |
| Abbvie | Meals · 2025-12-12 | Rinvoq | $23 |
| Novo Nordisk | Meals · 2025-12-05 | Wegovy | $18 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-12-03 | Entyvio | $27 |
| Ardelyx | Meals · 2025-11-21 | Ibsrela | $31 |
| Phathom Pharmaceuticals | Meals · 2025-11-07 | Voquezna | $21 |
| Pfizer | Meals · 2025-10-24 | Velsipity | $22 |
| Celltrion USA | Meals · 2025-10-10 | Vegzelma | $22 |
| Abbvie | Meals · 2025-10-03 | Skyrizi | $23 |
| Abbvie | Meals · 2025-09-26 | Rinvoq | $23 |
| Ipsen Biopharmaceuticals | Meals · 2025-09-12 | Iqirvo | $23 |
| Lilly USA | Meals · 2025-08-15 | Omvoh | $25 |
| Ardelyx | Meals · 2025-08-08 | Ibsrela | $22 |
| Lilly USA | Meals · 2025-07-31 | Omvoh | $33 |
| Abbvie | Meals · 2025-07-25 | Rinvoq | $21 |
| Abbvie | Meals · 2025-07-17 | Viberzi | $26 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-07-08 | Xifaxan | $19 |
| Lilly USA | Meals · 2025-07-07 | Omvoh | $35 |
| Conmed | Meals · 2025-07-02 | Conmed Biliary | $18 |
| Olympus Medical Systems | Consulting · 2025-06-25 | Evis Exera II Small Intestinal Videoscope | $3,206 |
| Celltrion USA | Meals · 2025-06-20 | Vegzelma | $22 |
| Abbvie | Meals · 2025-06-06 | Skyrizi | $33 |
| Lilly USA | Meals · 2025-05-19 | Omvoh | $35 |
| Ardelyx | Meals · 2025-05-09 | Ibsrela | $21 |
| Abbvie | Meals · 2025-04-25 | Rinvoq | $22 |
| Aimmune Therapeutics | Meals · 2025-04-22 | Zenpep | $27 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-04-15 | Entyvio | $32 |
| Abbvie | Meals · 2025-04-08 | Skyrizi | $31 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-19 | Entyvio | $28 |
| Lilly USA | Meals · 2025-03-11 | Omvoh | $35 |
| Janssen Biotech | Meals · 2025-03-07 | Tremfya | $26 |
| Abbvie | Meals · 2025-03-04 | Skyrizi | $18 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-28 | Entyvio | $9 |
| Abbvie | Meals · 2025-02-25 | Linzess | $24 |
| Pfizer | Meals · 2025-02-21 | Xeljanz | $23 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-11 | Entyvio | $19 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-01-31 | Entyvio | $22 |
| Braintree Laboratories | Meals · 2025-01-28 | Suflave | $23 |
| Janssen Biotech | Meals · 2025-01-24 | Tremfya | $30 |
| Janssen Biotech | Meals · 2025-01-17 | Tremfya | $37 |
| Abbvie | Meals · 2025-01-15 | Rinvoq | $29 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-01-10 | Xifaxan | $24 |
| Lilly USA | Meals · 2025-01-08 | Omvoh | $34 |
See earlier years (2024, 2023)
2024: $1,253
| Medtronic | Endoflip | $446 | 5 payments
|
| Abbvie | Rinvoq | $227 | 9 payments
|
| Lilly USA | Omvoh | $157 | 6 payments
|
| Janssen Biotech | Stelara | $111 | 4 payments
|
| Pfizer | Xeljanz | $106 | 5 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $104 | 5 payments
|
| Madrigal Pharmaceuticals | Resmetirom | $28 | 1 payment
|
| Intercept Pharmaceuticals | Ocaliva | $25 | 1 payment
|
| Ferring Pharmaceuticals | Rebyota | $25 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $24 | 1 payment
|
2023: $226
| Genzyme | Dupixent | $118 | 5 payments
|
| Pfizer | Xeljanz | $46 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $22 | 1 payment
|
| Janssen Biotech | Stelara | $22 | 1 payment
|
| Celltrion USA | Yuflyma | $17 | 1 payment
|
Professional record
- NPI
- 1225457211
- Licence
- CA 1147334
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X); Student in a training program (390200000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2014-04-07
- NPI last updated
- 2021-10-22
- NPI record certified
- 2021-10-22
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1100 Van Ness Ave, San Francisco, CA, 94109 · 3838 California St, San Francisco, CA, 94118